In instances of HGF-dependent c-MET activation, emibetuzumab obstructs HGF binding to c-MET, inhibiting c-MET phosphorylation and subsequent tumor growth suppression in both in vitro and in vivo settings. The gene discussed is MET; the disease is neoplasm.